Home » Stocks » ANIX

Anixa Biosciences, Inc. (ANIX)

Stock Price: $4.05 USD 0.10 (2.53%)
Updated Jun 21, 2021 12:29 PM EDT - Market open
Market Cap 118.30M
Revenue (ttm) 512,500
Net Income (ttm) -9.39M
Shares Out 28.67M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $4.05
Previous Close $3.95
Change ($) 0.10
Change (%) 2.53%
Day's Open 3.95
Day's Range 3.95 - 4.11
Day's Volume 27,507
52-Week Range 1.70 - 8.09

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN JOSE, Calif., May 26, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today ...

3 weeks ago - PRNewsWire

SAN JOSE, Calif., May 20, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today ...

1 month ago - PRNewsWire

HALLE (SAALE), Germany, May 7, 2021 /PRNewswire/ -- OntoChem GmbH, a German Life Science IT company, announced today that it has assigned its drug discovery technologies and assets, including its drug d...

1 month ago - PRNewsWire

Anixa Biosciences Inc (NASDAQ: ANIX) shares drop after the FDA has requested additional information on its Chimeric Antigen Receptor-T cell therapy (CAR-T) being developed in partnership with Moffitt Ca...

2 months ago - Benzinga

SAN JOSE, Calif., April 19, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced toda...

2 months ago - PRNewsWire

SAN JOSE, Calif., April 5, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today...

2 months ago - PRNewsWire

SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infecti...

2 months ago - PRNewsWire

SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc.  (NASDAQ: ANIX) ("Anixa" or the "Company"), a biotechnology company focused on the treatment and prevention of cancer and infecti...

2 months ago - PRNewsWire

SAN JOSE, Calif., March 22, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced toda...

2 months ago - PRNewsWire

SAN JOSE, Calif., March 12, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced toda...

3 months ago - PRNewsWire

Anixa Biosciences (ANIX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

SAN JOSE, Calif., July 10, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced...

11 months ago - PRNewsWire

SAN JOSE, Calif., July 6, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced ...

11 months ago - PRNewsWire

SAN JOSE, Calif., July 2, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced ...

11 months ago - PRNewsWire

Top Ranked Momentum Stocks to Buy for February 11th

Other stocks mentioned: ACBI, AFG
1 year ago - Zacks Investment Research

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jan 1, 1987
CEO
Amit Kumar
Employees
3
Stock Exchange
NASDAQ
Ticker Symbol
ANIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price forecast is 9.50, which is an increase of 134.57% from the latest price.

Price Target
$9.50
(134.57% upside)
Analyst Consensus: Strong Buy